Hearing improvement after bevacizumab in patients with neurofibromatosis type 2 - Wikidata - awgldk - TriplyDB

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2

http://www.wikidata.org/entity/Q30387415

about

An Update on the Ophthalmologic Features in the Phakomatoses Neurofibromatosis: an update of ophthalmic characteristics and applications of optical coherence tomography Medical management of brain tumors and the sequelae of treatment.Neuropilins: expression and roles in the epithelium A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation Secreted Factors from Human Vestibular Schwannomas Can Cause Cochlear Damage.The importance of nerve microenvironment for schwannoma development.Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.Molecular mechanisms and clinical applications of angiogenesis Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.Retrosigmoid Craniotomy for Auditory Brainstem Implantation in Adult Patients with Neurofibromatosis Type 2.Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth.Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model Low-dose bevacizumab induces radiographic regression of vestibular schwannomas in neurofibromatosis type 2: A case report and literature review Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma.Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Imatinib in neurofibromatosis type 2.mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.Hearing and facial function outcomes for neurofibromatosis 2 clinical trials.miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.Optimizing biologically targeted clinical trials for neurofibromatosis.NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations.Short-term histopathology effects of gamma knife radiosurgery on a vestibular schwannoma Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.Short-term clinico-radiographic response to super-selective intra-arterial cerebral infusion of Bevacizumab for the treatment of vestibular schwannomas in Neurofibromatosis type 2 Opportunities and challenges for successful use of bevacizumab in pediatrics.Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.Dysfunction of the cochlea contributing to hearing loss in acoustic neuromas: an underappreciated entity.Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.Mechanisms of hearing loss in neurofibromatosis type 2.AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.The molecular biology of vestibular schwannomas and its association with hearing loss: a review.

P2860

Q26738915-889D1F12-321E-489A-AA4E-689A482041DE Q26743449-6674A92C-07B0-4D4B-9A01-CF06FFEF1602 Q26992174-AE13CC93-8747-40C1-B93C-DA643A380E28 Q26998786-4F747D56-D601-48B1-BB3F-F3B5F203263B Q27301307-74179D92-CF75-42ED-A95C-B1E869885C0A Q27303070-D3F50720-4624-4722-A5A8-58FD2A2FA991 Q27321805-89519E0B-B24F-435B-AD9C-39A50746443D Q27853117-742FC12B-DE3B-4438-8766-DA9D2FC20290 Q27853151-FB98DB4D-3547-4429-A0E7-3FE3B2D136AF Q29547314-12B09A23-A587-4BAE-BEA2-E04FAB70D1C3 Q30357776-A41A5821-32BC-453C-8F5C-DE660B474C65 Q30359059-BB34D209-86D7-4244-9AB7-434B6D40F8CF Q30364937-3EB6D501-F506-4972-8B57-6CCCAC43EB56 Q30368779-EEE0A260-908F-41CA-8B8A-A25A8D224C28 Q30377885-072DB857-9C55-4F25-8BC9-AC3BB64B27D7 Q30383248-472995A5-B9DA-4D7E-9151-C2CCCC167B0C Q30385105-B6075562-F1C8-451A-BE2D-BD98FFEB4E64 Q30388655-9EBFFC1C-D7C8-4FF9-873F-F49B443D9586 Q30389069-AFD51ED9-90D7-4603-A76F-B0E5DF1BE41C Q30390781-CFC3E977-2A4A-47AE-9AE0-687F2899346F Q30393183-BF249B67-CD52-4B4C-A429-93E38240576C Q30399006-70685940-D1EE-457A-901B-7EF6F4EF389F Q30407175-4FC2120E-D876-43E7-8252-810257EC7E0A Q30415483-D26A04E3-252D-4BFD-963F-0AE2FC96BD2B Q30422022-ED1107EE-5D6C-4A90-BDA5-662E3B88AE6E Q30425761-580A7139-31EB-4742-A3C9-8E30A0D79AC0 Q30428483-D36D389E-423B-44C9-A55A-638EDBE63C8A Q30438136-4CC4E9C7-5A62-4036-BDEE-59902D26C31E Q30438898-9298F107-25BE-42C9-B75D-211977D6DE2D Q30440530-B6E1CFAA-150C-4CEA-8C2A-20E824DA947D Q30445857-0639044D-51B4-4F6D-8046-65B601F0972A Q30450038-79E57572-9D9A-4280-B490-E95483179100 Q30454047-995066FE-AFA3-49F5-AE88-E9B8EC1C31F8 Q30454883-9FF7D348-081E-4F09-9359-3294E70507AE Q30455709-A10A75E8-DD85-4A88-B853-4A0741617126 Q30455944-D472EF86-BC08-4118-A91E-7C9C637AC6B4 Q30458310-CFF77806-52C5-4403-AB1C-5AB59F292BB0 Q30462725-CA106137-BCC2-4A77-A7D8-F1732C4C04DC Q30464276-B13F20F9-CEA5-424D-A958-5A8B8F06D22D Q30467803-0F4CF19C-0E8D-4BA0-8FFF-638A3F76C406

P2860

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2

http://www.wikidata.org/entity/Q30387415

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2

@ast

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2

@en

type

label

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2

@ast

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2

@en

prefLabel

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2

@ast

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2

@en

P1433

Q30387415-959DA33D-550C-4A47-ADBF-277C76E996A4

P1476

Q30387415-95902BC1-8D69-4DF6-AA9E-7CBC9C12BB1C

P2093

Q30387415-06892B74-5E3D-4BAE-9BDB-4B63CCFFD6AE

Q30387415-341A3BD3-320C-4212-A0B2-9730040FDC29

Q30387415-40161C39-D9A1-4A0F-BE88-BD143D9E32B8

Q30387415-4FC212A8-BD8B-481E-B45C-F4E202357F5F

Q30387415-6ACD8BA9-39DD-4883-9F3E-CD46E156D7B9

Q30387415-ADC06FDE-158A-4437-844F-6299172A5862

Q30387415-D911C934-E0D0-4CE8-B69E-42B1F66B191B

Q30387415-FD413887-4F52-44CB-9244-6FBD95AE8A48

P2860

Q30387415-0007FFA3-47EF-4FD4-A5F7-E508835CB46C

Q30387415-03D9152F-B5A8-40B0-964C-6C63B91D19CF

Q30387415-181E8CA2-D298-4627-ACF5-AAE333EA9D9B

Q30387415-2AAFF75B-4888-442D-9033-715C12714D10

Q30387415-2AFC8679-A2DA-4F1B-9C30-499F85C26F7F

Q30387415-32A9A15D-F835-4DB5-B880-544CB73ED69F

Q30387415-3309B03D-B3F1-4AA0-BB8F-8A892956BBB5

Q30387415-35F39039-356B-4679-BFE5-B5411B8DD7C4

Q30387415-39888573-8A88-4355-BF60-CF371A05B4B4

Q30387415-3C0FB995-C12E-4DA1-B2CF-24BA3C3733E0

P304

Q30387415-A88703C4-22EF-41DE-8CAB-9A1DC55B32B7

P31

Q30387415-B780E363-AFEC-41AD-99E1-E7E1074C6ED0

P356

Q30387415-7AEDB70C-47D8-43A8-8C11-AB84404BCB09

P407

Q30387415-A9D84D01-11FB-4283-92DF-86ECED5AB33A

P433

Q30387415-66AF8FD4-4B41-4CAB-9628-274F8300118E

P478

Q30387415-0B1BEEF6-8C17-47FC-841F-D2357E95E11C

P50

Q30387415-F24F3C88-31CD-45D9-A044-73D680A11B58

P577

Q30387415-F289D53E-8C84-4D67-93FF-5DBE84D742AC

P698

Q30387415-59322711-43EA-411A-A1D5-00291254BDED

P921

Q30387415-A796D640-8500-46F4-B1D5-6ADD69032F56

P932

Q30387415-5B341DC7-0EA8-4A28-9E6D-7D5B4006C570

P356

P1433

The New England Journal of Medicine

P1476

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2

@en

P2093

A Gregory Sorensen

http://www.w3.org/2001/XMLSchema#string

Alex Tyrrell

http://www.w3.org/2001/XMLSchema#string

Anat O Stemmer-Rachamimov

http://www.w3.org/2001/XMLSchema#string

Chris Halpin

http://www.w3.org/2001/XMLSchema#string

Emmanuelle di Tomaso

http://www.w3.org/2001/XMLSchema#string

Fred G Barker

http://www.w3.org/2001/XMLSchema#string

Rakesh K Jain

http://www.w3.org/2001/XMLSchema#string

Scott R Plotkin

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor angiogenesis: therapeutic implications

Angiogenesis in cancer and other diseases

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.

NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update.

Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought.

Improved preservation of hearing and facial nerve function in vestibular schwannoma surgery via the retrosigmoid approach in a series of 200 patients.

P304

358-367

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA0902579

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

361

http://www.w3.org/2001/XMLSchema#string

P50

Timothy P Padera

P577

2009-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19587327

http://www.w3.org/2001/XMLSchema#string

P921

P932

4816642

http://www.w3.org/2001/XMLSchema#string